Central America Pharmaceuticals & Healthcare Report

Published 30 January 2015

  • 61 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Central America Pharmaceuticals & Healthcare Report

BMI View: A growing ageing population, favourable tax incentives and high demand for medicines confirm Central America's ability to continue offering revenue-generating opportunities to foreign drugmakers. However , the region's growing preference for traditional medicines could interfere with productive sales in coming years.

Headline Expenditure Projections

  • Pharmaceuticals: USD3.7bn in 2014 to USD3.9bn in 2015; +5.6%. Our forecast has been revised upwards since Q115 due to historical data.

  • Healthcare: USD16.8bn in 2014 to USD17.8bn in 2015; +5.7 %. Our forecast has been revised upwards since Q115 due to revised historical data.

Risk/Reward Index

Based on our analysis and assessment of the market's appeal to pharmaceutical companies in our Q215 Pharmaceutical Risk/Reward Index (RRIs), the Americas scores 50.9 out of 100, below Western Europe (67.4), Asia Pacific (52.9), and Central and Eastern Europe (51.1), but above the Middle East and Africa (42.5). Of the seven Central American countries surveyed Panama's RRI score ranks first at 44.0, followed by Costa Rica (43.2), Guatemala (38.8), Belize (37.8), Honduras (37.0), Nicaragua (35.5) and El Salvador (35.0).

Key Trends And Developments

  • In January 2015, delegates from Panama's Ministry of Health travelled to Costa Rica in order to seek advice on Panama's plans to create a unified health system. The two countries plan to work together in order to strengthen Panamanian healthcare in coming years.

  • In December 2014, the Honduran Ministry of Health signed an agreement with the National Anti-Corruption Council (CNA) under which the Ministry will facilitate the surveillance of the delivery and distribution of medicines and other medical supplies throughout the country. This agreement will also help to fight the recent rise in general nationwide corruption.

  • In December 2014, Costa Rica created the National Commission on Health Research (CONIS). CONIS is recognised through Article 34 of Law 9234, which was...

Table of Contents

BMI Industry View
7
SWOT
9
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Central America Minus Mexico Pharmaceutical Sales, Historic Data And Forecasts
11
Guatemala
11
Table: Guatemala Pharmaceutical Sales Forecasts
12
Costa Rica
12
Table: Costa Rica Pharmaceutical Sales Forecasts
13
El Salvador
13
Table: El Salvador Pharmaceutical Sales Forecasts
14
Honduras
14
Table: Honduras Pharmaceutical Sales Forecasts
15
Panama
15
Table: Panama Pharmaceutical Sales Forecasts
15
Nicaragua
16
Table: Nicaragua Pharmaceutical Sales Forecasts
16
Belize
17
Table: Belize Pharmaceutical Sales Forecasts
17
Healthcare Market Forecast
18
Table: Central America Minus Mexico Healthcare Expenditure Trends, Historical Data and Forecasts
19
Guatemala
19
Table: Guatemala Healthcare Expenditure Forecasts
19
Costa Rica
19
Table: Costa Rica Healthcare Expenditure Forecasts
20
El Salvador
20
Table: El Salvador Healthcare Expenditure Forecasts
22
Panama
22
Table: Panama Healthcare Expenditure Forecasts
23
Honduras
23
Table: Honduras Healthcare Expenditure Forecasts
24
Nicaragua
24
Table: Nicaragua Healthcare Expenditure Forecasts
24
Belize
25
Table: Belize Healthcare Expenditure Forecasts
25
Pharmaceutical Trade Forecast
26
Guatemala
27
Table: Guatemala Pharmaceutical Trade Data And Forecasts (USDmn)
28
Costa Rica
28
Table: Costa Rica Pharmaceutical Trade Data And Forecasts (USDmn)
28
El Salvador
29
Table: El Salvador Pharmaceutical Trade Data And Forecasts (USDmn)
29
Panama
29
Table: Panama Pharmaceutical Trade Data And Forecasts (USDmn)
30
Honduras
30
Table: Honduras Pharmaceutical Trade Data And Forecasts (USDmn)
30
Nicaragua
31
Table: Nicaragua Pharmaceutical Trade Data And Forecasts (USDmn)
31
Belize
31
Industry Risk Reward Ratings
32
Americas Risk/Reward Ratings
32
Central America Risk/Reward Ratings
38
Industry Trends And Developments
39
Regional Developments
39
Guatemala
41
Costa Rica
42
El Salvador
46
Panama
48
Honduras
48
Nicaragua
50
Belize
51
Epidemiology
52
Clinical Trials
53
Regulatory Development
56
Intellectual Property Regime
56
Costa Rica
57
El Salvador
58
Honduras
58
Nicaragua
59
Panama
59
Guatemala
59
Competitive Landscape
60
Company Profile
61
Ancalmo Internacional
61
Donovan Werke
63
Glossary
65
Methodology
67
Pharmaceutical Expenditure Forecast Model
67
Healthcare Expenditure Forecast Model
67
Notes On Methodology
68

The Central America Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Central America Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras, to test other views - a key input for successful budgeting and strategic business planning in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc